In a recent bid Pandion Therapeutics Inc. [PAND] faced a contemporary bid of $15.30 yielding a 15.47% incline where 0.5 million shares have exchanged hands over the last week. PAND amount got a boost by 0.59% or $0.09 versus $15.21 at the end of the prior session. This change led market cap to move at 436.82M, putting the price 48.83% below the 52-week high and -44.87% above the 52-week low. The company’s stock has a normal trading capacity of 0.5 million shares while the relative volume is 4.20.
On 16, November 2020, Pandion Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update. According to news published on Yahoo Finance, – Enrollment and dosing complete in Phase 1a clinical trial of PT101; top-line results expected early 2021- PT627 systemic PD-1 agonist development candidate nominated; IND-enabling studies expected to initiate 4Q 2020- Presented preclinical data at FOCIS 2020 highlighting potential of TALON platform in autoimmune disease.
Analyst Birdseye View:
The most recent analyst activity for Pandion Therapeutics Inc. [NASDAQ:PAND] stock was on August 11, 2020, when it was Initiated with an Overweight rating from Morgan Stanley, which also raised its 12-month price target on the stock to $25. Before that, on August 11, 2020, SVB Leerink Recapitulated an Outperform rating and elevated its amount target to $24. On August 11, 2020, Goldman Initiated a Buy rating and boosted its price target on this stock to $28. On August 10, 2020, BMO Capital Markets Initiated an Outperform rating and increased its price target to $29.
In the past 52 weeks of trading, this stock has oscillated between a low of $10.28 and a peak of $27.75. Right now, according to Wall Street analyst the average 12-month amount target is $26.50. At the most recent market close, shares of Pandion Therapeutics Inc. [NASDAQ:PAND] were valued at $15.30.
This publicly-traded organization’s revenue is $26,135 per employee, while its income is -$698,703 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -155.53, -427.38, -249.88 and -290.73 respectively.
If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 46.80 and the whole liability to whole assets at 17.49. It shows enduring liability to the whole principal at 46.80 and enduring liability to assets at 0.17 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 14.82 points at 1st support level, the second support level is making up to 14.33. But as of 1st resistance point, this stock is sitting at 15.78 and at 16.25 for 2nd resistance point.
Pandion Therapeutics Inc. [PAND] reported its earnings at -$0.51 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.44/share signifying the difference of -0.07 and -15.90% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$10.15 calling estimates for -$0.61/share with the difference of -9.54 depicting the surprise of -1,563.90%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Pandion Therapeutics Inc. [NASDAQ:PAND] is 6.60. Likewise, the Quick ratio is also the same, showing Cash ratio at 2.27.
The most recent insider trade was by Becker Daniel J., Director, and it was the purchase of 14197.0 shares on Nov 18. Becker Daniel J., the Director, completed a purchase of 15197.0 shares on Nov 17.